Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:NKTX NASDAQ:RADX NASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.28-35.8%$2.62$1.93▼$4.94$130.65M3.341.50 million shs8.36 million shsNKTXNkarta$3.03$2.61$1.63▼$3.65$216.78M0.88818,309 shs356,284 shsRADXRadiopharm Theranostics$4.63+0.7%$4.51$3.62▼$16.25$54.70M1.2843,757 shs15,821 shsTKNOAlpha Teknova$3.89+0.5%$3.19$1.91▼$6.68$208.56M0.47101,752 shs134,031 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%-17.09%-26.45%-2.15%+12.32%NKTXNkarta0.00%+14.77%+1.68%+30.04%+78.24%RADXRadiopharm Theranostics0.00%-1.70%+2.21%-7.03%+10.77%TKNOAlpha Teknova0.00%+10.83%+28.38%+88.83%-40.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.28-35.8%$2.62$1.93▼$4.94$130.65M3.341.50 million shs8.36 million shsNKTXNkarta$3.03$2.61$1.63▼$3.65$216.78M0.88818,309 shs356,284 shsRADXRadiopharm Theranostics$4.63+0.7%$4.51$3.62▼$16.25$54.70M1.2843,757 shs15,821 shsTKNOAlpha Teknova$3.89+0.5%$3.19$1.91▼$6.68$208.56M0.47101,752 shs134,031 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%-17.09%-26.45%-2.15%+12.32%NKTXNkarta0.00%+14.77%+1.68%+30.04%+78.24%RADXRadiopharm Theranostics0.00%-1.70%+2.21%-7.03%+10.77%TKNOAlpha Teknova0.00%+10.83%+28.38%+88.83%-40.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$10.00338.60% UpsideNKTXNkarta 2.80Moderate Buy$10.75254.79% UpsideRADXRadiopharm Theranostics 2.00Hold$16.00245.57% UpsideTKNOAlpha Teknova 2.33Hold$8.00105.66% UpsideCurrent Analyst Ratings BreakdownLatest RADX, NKTX, TKNO, and BDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.005/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/13/2026NKTXNkarta Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.004/23/2026BDTXBlack Diamond Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.87$0.53 per share4.32$1.82 per share1.25NKTXNkartaN/AN/AN/AN/A$4.00 per shareN/ARADXRadiopharm Theranostics$2.35M23.27N/AN/A$3.52 per share1.32TKNOAlpha Teknova$40.52M5.15N/AN/A$1.21 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)NKTXNkarta-$104.08M-$1.34N/AN/AN/AN/A-30.90%-24.20%8/11/2026 (Estimated)RADXRadiopharm Theranostics-$24.83MN/AN/AN/AN/AN/AN/AN/AN/ATKNOAlpha Teknova-$17.26M-$0.32N/AN/AN/A-41.07%-24.32%-16.34%8/6/2026 (Estimated)Latest RADX, NKTX, TKNO, and BDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026NKTXNkarta-$0.39-$0.37+$0.02-$0.37N/AN/A5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A5/6/2026Q1 2026TKNOAlpha Teknova-$0.0926-$0.08+$0.0126-$0.08$10.23 million$11.08 million3/25/2026Q4 2025NKTXNkarta-$0.32-$0.37-$0.05-$0.37N/AN/A3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/A2/26/2026Q4 2025TKNOAlpha Teknova-$0.09-$0.09N/A-$0.09$9.62 million$9.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ARADXRadiopharm TheranosticsN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46NKTXNkartaN/A12.9612.96RADXRadiopharm TheranosticsN/A3.01N/ATKNOAlpha Teknova0.204.593.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%NKTXNkarta80.54%RADXRadiopharm TheranosticsN/ATKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%NKTXNkarta8.40%RADXRadiopharm TheranosticsN/ATKNOAlpha Teknova12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableNKTXNkarta14071.54 million65.54 millionOptionableRADXRadiopharm TheranosticsN/A11.81 millionN/AN/ATKNOAlpha Teknova24053.61 million46.91 millionNot OptionableRADX, NKTX, TKNO, and BDTX HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO) and REPRO-MED Systems (KRMD)May 9, 2026 | theglobeandmail.comAlpha Teknova, Inc. (NASDAQ:TKNO) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 9, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comAlpha Teknova Charts Cautious Path to 2027 GrowthMay 7, 2026 | tipranks.comAlpha Teknova Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comAlpha Teknova (TKNO) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comAlpha Teknova (NASDAQ:TKNO) Posts Earnings Results, Beats Expectations By $0.01 EPSMay 6, 2026 | marketbeat.comTeknova Reports First Quarter 2026 Financial ResultsMay 6, 2026 | globenewswire.comAlpha Teknova (TKNO) to Release Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comTeknova to Report First Quarter 2026 Financial Results on May 6, 2026April 22, 2026 | globenewswire.comFavourable Signals For Alpha Teknova: Numerous Insiders Acquired StockMarch 30, 2026 | finance.yahoo.comAlpha Teknova (NASDAQ:TKNO) CEO Acquires $55,900.00 in StockMarch 10, 2026 | insidertrades.comTeknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilitiesFebruary 27, 2026 | seekingalpha.comAlpha Teknova Inc (TKNO) Q4 2025 Earnings Call Highlights: Navigating Growth Amid ChallengesFebruary 27, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | seekingalpha.comTeknova Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 26, 2026 | globenewswire.comEarnings To Watch: Alpha Teknova Inc (TKNO) Reports Q4 2025 ResultFebruary 25, 2026 | finance.yahoo.comAlpha Teknova (TKNO): Investors are Waiting for Leading Indicators to Drive SalesFebruary 20, 2026 | insidermonkey.comTeknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026February 5, 2026 | globenewswire.comWhy Alpha Teknova, Inc.’s (TKNO) Stock Is Down 13.01%December 22, 2025 | aaii.comAAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Voyager Therapeutics (VYGR) and Terns Pharmaceuticals (TERN)November 13, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRADX, NKTX, TKNO, and BDTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$2.28 -1.27 (-35.77%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.34 +0.06 (+2.63%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Nkarta NASDAQ:NKTX$3.03 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.03 0.00 (0.00%) As of 05/22/2026 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Radiopharm Theranostics NASDAQ:RADX$4.63 +0.03 (+0.65%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$4.62 -0.01 (-0.13%) As of 05/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.Alpha Teknova NASDAQ:TKNO$3.89 +0.02 (+0.52%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.90 +0.00 (+0.13%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
